Earnings Feed
Start Free
CYTOKINETICS INC·4

Mar 17, 4:11 PM ET

Blum Robert I 4

4 · CYTOKINETICS INC · Filed Mar 17, 2026

Research Summary

AI-generated summary of this filing

Updated

Cytokinetics (CYTK) CEO Robert Blum Receives Equity Award

What Happened

Robert I. Blum, President & CEO and a Director of Cytokinetics (CYTK), received annual equity awards reported on March 17, 2026 for transactions dated March 15, 2026. The filing shows:

  • 75,258 restricted stock units (RSUs) granted (convert 1:1 to common shares);
  • 113,529 derivative awards (1,665 and 111,864 units) reported as acquisitions of derivative securities, consistent with stock option awards. All awards were reported with an acquisition price of $0.00 (typical for grants/awards). These are compensation grants (not open‑market purchases or sales).

Key Details

  • Transaction date: March 15, 2026; Form 4 filed March 17, 2026 (filed within the typical 2-business‑day Form 4 window).
  • Reported amounts: 75,258 RSUs; 1,665 and 111,864 derivative units (total 113,529 derivative awards). Acquisition price reported as $0.00.
  • Vesting: RSUs vest 40% after 1 year, 40% after 2 years, and 20% after 3 years (per F1). Stock options vest in 48 equal monthly installments (per F4/F5).
  • Shares owned after the transaction are not specified in the provided summary of the filing.
  • Footnotes: F1 describes RSU vesting; F4/F5 describe option vesting; F2/F3 indicate certain shares are held in family trusts.

Context

  • These entries are awards (code A) — compensation grants to an executive — and not sales or purchases in the open market. Options/derivative awards are not exercises; they represent the right to acquire shares in the future subject to vesting.
  • Awards like RSUs and options are routine executive compensation and do not by themselves indicate a buy or sell signal.

Insider Transaction Report

Form 4
Period: 2026-03-15
CYTOKINETICS INCCYTK
Blum Robert I
DirectorPresident & CEO
Transactions
  • Award

    Common Stock

    [F1]
    2026-03-15+75,258→ 466,931 total
  • Award

    Incentive Stock Option (Right to Buy)

    [F4]
    2026-03-15+1,665→ 1,665 total
    Exercise: $60.06From: 2026-04-15Exp: 2036-03-14→ Common Stock (1,665 underlying)
  • Award

    Non-Qualified Stock Option (Right to Buy)

    [F5]
    2026-03-15+111,864→ 111,864 total
    Exercise: $60.06From: 2026-04-15Exp: 2036-03-14→ Common Stock (111,864 underlying)
Holdings

  • Common Stock

    [F2]
    (indirect: By Trust)
    2,083

  • Common Stock

    [F3]
    (indirect: By Trust)
    2,083
Footnotes (5)
  • [F1]Annual equity award comprised of restricted stock units ("RSUs") that convert on a 1:1 basis for shares of our common stock. RSUs vest, subject to the officer's continued employment with the company, as follows: 40% of the RSUs on the 1-year anniversary of the grant date, an additional 40% of the RSUs on the 2-year anniversary of the grant date, and the final 20% of the RSUs on the 3-year anniversary of the grant date. RSUs are subject to the company's Amended and Restated 2004 Equity Incentive Plan.
  • [F2]Shares held by The Bridget Blum 2003 Irrevocable Trust.
  • [F3]Shares held by The Brittany Blum 2003 Irrevocable Trust.
  • [F4]Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan.
  • [F5]Annual equity award comprised of stock options that vest in 48 equal monthly installments, subject to officer's continued employment with the company on each vesting date. Stock options are subject to the company's Amended and Restated 2004 Equity Incentive Plan.
Signature
/s/ John O. Faurescu, attorney-in-fact for Mr. Blum|2026-03-17

Documents

1 file
  • 4
    form4.xmlPrimary

    PRIMARY DOCUMENT